Posted by Michael Wonder on 11 Jun 2025
Cantargia’s nadunolimab antibody awarded US FDA fast track designation
11 June 2025 - Cantargia today announced that the US FDA has granted fast track designation to nadunolimab, Cantargia's anti-IL1RAP antibody for the treatment of patients with previously untreated metastatic pancreatic ductal adenocarcinoma with high expression levels of IL1RAP in combination with gemcitabine and nab-paclitaxel.
The fast track designation follows strong clinical data from the CANFOUR study showing a two-year survival of 35%, an overall survival of 14.2 months and overall response rate of 48% in this patient population.
